Calprotectin

ALPCO Announces the Commercial Launch of its FDA 510(k) Cleared Calprotectin Immunoturbidimetric Assay

Retrieved on: 
Tuesday, December 19, 2023
IBD, IBS, Crohn's disease, FDA, Calprotectin, Inflammatory bowel disease, UC, Hospital, Irritable bowel syndrome, Patient, Automation, Ulcerative colitis, Asset management

SALEM, N.H., Dec. 19, 2023 /PRNewswire/ -- American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, proudly announces the commercial launch of its FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay, enhancing its suite of Gastrointestinal (GI) diagnostic solutions.

Key Points: 
  • SALEM, N.H., Dec. 19, 2023 /PRNewswire/ -- American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, proudly announces the commercial launch of its FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay, enhancing its suite of Gastrointestinal (GI) diagnostic solutions.
  • The new Calprotectin Immunoturbidimetric Assay is a strategic addition to ALPCO's comprehensive GI solutions menu.
  • In July 2023, ALPCO unveiled the Calprotectin Immunoturbidimetric Assay at the American Association for Clinical Chemistry (now ADLM) annual meeting.
  • ALPCO has always been dedicated to blending the benefits of automation with expertise in immunoassays, a commitment that is exemplified in the Calprotectin Immunoturbidimetric Assay.

EnLiSense CCM To Advance IBD Care with Innovative Sweat Sensor Studies, Teams Up with Leading Clinicians

Retrieved on: 
Wednesday, October 4, 2023
Technology, Biotechnology, Health, Other Health, Professional Services, Research, Medical Devices, Software, General Health, Data Analytics, Genetics, Health Technology, Science, Data Management, Brain-derived neurotrophic factor, University, Crohn's & Colitis Foundation, GFAP, IBD, University of Texas at Austin, Melatonin, Interleukin 6, Biomarker, Glial fibrillary acidic protein, IL6, University of Glasgow, Crohn's disease, Patient, CRP, Physician, Conditional sentence, Inflammatory bowel disease, BDNF, Glucose, Skin, C-reactive protein, Pharmaceutical industry, Medical imaging, Cortisol, Calprotectin, CCM

Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.

Key Points: 
  • Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.
  • The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat.
  • This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.
  • Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging.

NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost

Retrieved on: 
Wednesday, April 12, 2023
Health Technology, Other Consumer, Biotechnology, Finance, Women, Seniors, Other Science, Health, Research, Professional Services, Men, Consumer, Other Technology, Nanotechnology, Wearables, Mobile Technology, Science, Other Health, Hardware, Data Management, Managed Care, Telemedicine, Virtual Medicine, General Health, Technology, Biometrics, Medical Devices, Translation, University, Icahn School of Medicine at Mount Sinai, IBD, AWARE, Quality of life, Cortisol, Mount Sinai, Interleukin 6, Inflammation, Biomarker, IL6, Inflammatory bowel disease, Organization, Patient, Investment, CRP, Risk, Recurrence, Perspiration, Skin, Disease, C-reactive protein, Financial adviser, Medical imaging, Pharmaceutical industry, Calprotectin

IBD AWARE is an inflammation tracker targeting key biomarkers associated with inflammatory bowel disease (IBD).

Key Points: 
  • IBD AWARE is an inflammation tracker targeting key biomarkers associated with inflammatory bowel disease (IBD).
  • Additional details about the IBD AWARE platform and how it works can be found at https://www.ibdwearable.com .
  • “IBD AWARE will provide patients and their clinicians with the real-time, actionable data they need to further quality of life outcomes.
  • The Crohn’s & Colitis Foundation launched IBD Ventures to accelerate the discovery and development of research-based products with the potential to address unmet needs of IBD patients.

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022

Retrieved on: 
Tuesday, December 27, 2022
MWF, White matter, CSO, Calprotectin, ICH, Pharmacokinetics, ADAS, Disability, Board of High School and Intermediate Education Uttar Pradesh, New Drug Application, Thalamus, Principal, GLP, SPMS, Inflammation, BWH, Neurology, Alzheimer's disease, Toxicology, Male, Timed, Trial of the century, Pharmacist, CD, R, Disease, Research, Patient, Cerebellum, Infection, Safety, Expanded Disability Status Scale, PET, FDA, Therapy, IND, EDSS, CMSC, EA, PIND, NSCLC, MD–PhD, Doctor of Philosophy, Pharmaceutical industry, Vaccine, Management, MD, Foralumab

LONDON, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2022.

Key Points: 
  • LONDON, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2022.
  • These protocol amendments or revisions are intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.
  • These results confirm the previously reported data, from the first SPMS patient after three months of treatment of the first SPMS patient.
  • For the six months to 30 June 2022 the consolidated Group made a loss of $8.3m (six months to 30 June 2021: $17.0m).

SENTINEL DIAGNOSTICS LAUNCHES A TOTALLY AUTOMATED HIGH THROUGHPUT ANALYZER FOR FECAL IMMUNOCHEMICAL TESTING

Retrieved on: 
Wednesday, June 15, 2022
Sentinel, Laboratory, Cancer, Occult blood, CRC, Mortality, Inflammation, FIT, Molecular diagnostics, Feces, Colorectal cancer, Marketing, Fecal occult blood, Clinical chemistry, Immunochemistry, Analyser, Western world, Death, Automation, Diagnosis, Multimedia, Degenerative disease, Non-functional testing, Medical device, Calprotectin

Those screening programs are testing millions of people every year and this creates new challenges in the practical organization of the laboratories.

Key Points: 
  • Those screening programs are testing millions of people every year and this creates new challenges in the practical organization of the laboratories.
  • The new high throughput analyzer SENTiFIT800 can meet the need of throughput, automation and accuracy of the most demanding situation.
  • "For almost 20 years, Sentinel Diagnostics has supported the fight against colorectal cancer with high quality FOB Gold test and analyzers," explains Marco Buonaguidi, Head of Sales and Marketing.
  • The SENTiFIT800 Analyzer is a high-end system dedicated to fecal testing able to process up to 550 test/h, 1 million tests every year samples in total automation and full traceability.

SENTINEL DIAGNOSTICS LAUNCHES A TOTALLY AUTOMATED HIGH THROUGHPUT ANALYZER FOR FECAL IMMUNOCHEMICAL TESTING

Retrieved on: 
Wednesday, June 15, 2022
Sentinel, Laboratory, Cancer, Occult blood, CRC, Mortality, Inflammation, FIT, Molecular diagnostics, Feces, Colorectal cancer, Marketing, Fecal occult blood, Clinical chemistry, Immunochemistry, Analyser, Western world, Death, Automation, Diagnosis, Degenerative disease, Non-functional testing, Medical device, Calprotectin

Those screening programs are testing millions of people every year and this creates new challenges in the practical organization of the laboratories.

Key Points: 
  • Those screening programs are testing millions of people every year and this creates new challenges in the practical organization of the laboratories.
  • The new high throughput analyzer SENTiFIT800 can meet the need of throughput, automation and accuracy of the most demanding situation.
  • "For almost 20 years, Sentinel Diagnostics has supported the fight against colorectal cancer with high quality FOB Gold test and analyzers," explains Marco Buonaguidi, Head of Sales and Marketing.
  • The SENTiFIT800 Analyzer is a high-end system dedicated to fecal testing able to process up to 550 test/h, 1 million tests every year samples in total automation and full traceability.

Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease

Retrieved on: 
Friday, February 4, 2022
IND, Safety, Patient, Inflammation, Hospital, Food, Frontiers Media, Trial of the century, Ulcerative colitis, CRU, Immunotherapy, Cytokine, Crohn's disease, Technology, SAD, Capsule, Mab, Autoimmunity, COVID-19, Degenerative disease, Population, Drug discovery, PD, Company, GLOBE, Calprotectin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Industry, FDA, IV, Pharmaceutical industry, Regulatory T cell, Foralumab, Foralumab

NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced submission of an amendment to an Investigational New Drug (IND) application for evaluation of orally administered capsules of foralumab, which it believes would be the first “take home” immunotherapy, in patients with mild-to-moderately active Crohn’s Disease. If accepted by the U.S. Food and Drug Administration (FDA), the amendment is expected to expedite patient enrollment and completion of the foralumab Phase 1b study by the fourth quarter of 2022.

Key Points: 
  • The currently planned Phase 1b study with an amended protocol is designed as a placebo-controlled, randomized and dose-escalating trial, in mild-to-moderate patients with Crohns Disease.
  • This amendment would allow for the investigation of a broader patient population as well as a shorter dosing period.
  • The clinical findings from this Phase 1b study could support moving foralumab into a Phase 2 clinical trial in patients with mild-to-moderate Crohns Disease.
  • Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn's disease.

Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 10, 2021
UC, Autoimmunity, GI, CRP, Inflammation, IE, Therapy, R, G&A, Patient, Histology, Rheumatoid arthritis, Biology, Calprotectin, U.S. Securities and Exchange Commission, GMP, Technology, Security (finance), Securities Exchange Act of 1934, Ulcerative colitis, Terminology, Securities Act of 1933, Nasdaq, AMTI, AMT, SEC, Investment, Disease, GLOBE, CA, Microbiome, Growth, Magazine, Inflammatory Bowel Diseases, Epithelium, Pharmaceutical industry, Cryptocurrency, Medical device, Fine chemical

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Total R&D expenses for the second quarter of 2021 were $16.5 million, compared to $12.8 million for the same period in 2020.
  • Total G&A expenses for the second quarter of 2021 were $7.1 million, compared to $2.5 million for the same period in 2020.
  • Net loss for the second quarter of 2021 was $23.6 million, compared to $15.4 million for the same period in 2020.
  • Active transport is an efficient mechanism that uses the cells own machinery to transport materials across the IE barrier.